Brachytherapy is an effective and safe salvage option for re-irradiation in recurrent glioblastoma (rGBM): a systematic review

Glioblastoma (GBM) is classified as a grade IV astrocytoma by the World Health Organization (WHO), which is the most aggressive and common type of glioma[1]. For newly diagnosed GBM, the current treatment regimens typically include maximal safe surgical resection[2], followed by adjuvant radiotherapy and chemotherapy (external beam radiotherapy combined with temozolomide)[3 –5], or tumor-treating fields (TTFields)[6–7], and their reasonable combined regimens. Despite the use of this aggressive multidisciplinary strategy, the median survival time is only about 1/2-year, and the 5-year survival rate is only about 10%, or even lower[4–5,7].
Source: Radiotherapy and Oncology - Category: Radiology Authors: Source Type: research